Medication Instructions: Is Eltrombopag/Eltrombopag on the market?

Eltrombopag/ Eltrombopag is used to treat low platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP) when certain other drugs or surgery to remove the spleen are not effective. ITP is a condition that may cause abnormal bruising or bleeding due to an abnormally low number of platelets in the blood. It is also used to treat thrombocytopenia (low platelet count) in patients with chronic hepatitis C, allowing them to initiate and maintain interferon-based therapy.

Eltrombopag was initially approved by the U.S. Food and Drug Administration (FDA) in November 2008 under the trade name Promacta (only in the United States); In 2017, the United States adopted eltrombopag as a standard drug for the treatment of aplastic anemia. In 2010, the European Medicines Agency (EMA) concluded that the benefits of eltrombopag outweighed its risks, and it could be authorized for use in the EU and sold under the trade name Revolade (except in the United States). Then in 2022, it was approved by the State Food and Drug Administration in China and sold under the name Eltrombopag ethanolamine tablets (Revolade), and entered the scope of Class B medical insurance reimbursement.

Currently, the price of Eltrombopag original drug sold domestically is more than more than 4,000 RMB, and the Eltrombopag original drug sold overseas has Turkish and Indian versions, and the price may be more than more than 1,000 RMB (the price may fluctuate due to the exchange rate). Generic drugs of eltrombopag are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of the drug produced by a Bangladeshi pharmaceutical factory may be several hundred yuan (the price may fluctuate due to the exchange rate).